Eric Boutin, dRx Capital – Board Observer

Eric Boutin is a digital health investor and serial entrepreneur. Previously, Eric was Founder and CEO of Evolve, a machine-learning mobile technology company, which was acquired by HubSpot (NYSE: HUBS). He was Founder and CEO of Good Start Genetics, a molecular diagnostics and women’s health company, which acquired by Invitae (NYSE: NVTA). He was Founder and VP of Corporate Development at Flex Pharma, a biopharmaceutical company developing treatments for neuromuscular disorders, which went on to IPO (NSADAQ: FLKS).

Eric was an Investor and Entrepreneur in Residence at Longwood Fund, where he focused on healthcare and life science deals. He was a Founder of the HBS Alumni Angels Association of Boston, which provides seed capital for local startup companies. He is also a Venture Partner at NexGen Venture Partners, a network of entrepreneurs who co-invest in early stage tech companies. Eric holds a B.A. from Duke University, and an M.B.A. from Harvard Business School. In his free time, he enjoys weightlifting, science fiction, live theater, 80s rock, and Boston sports.

Eric is a board observer at Aspen RxHealth, Cala Health, Flywheel, Freenome, Peptone, and RxVantage. He is based out of Cambridge, Massachusetts.

Jason Chicola, Rev.com

Jason Chicola is the founder and CEO of Rev.com. Rev’s mission is to create great work-anywhere jobs, powered by AI. His vision for Rev.com is to unlock the full potential of speech for everyone, everywhere. Prior to starting Rev, Jason was the 3rd employee at Upwork (Nasdaq: UPWK), the largest online labor marketplace. Jason has also worked in private equity (H.I.G. Capital), venture capital (Globespan Capital), and consulting (McKinsey). Jason is an active angel investor and has made over a dozen seed and Series A investments, with a focus on online marketplaces. Jason earned his Bachelor of Science degrees in Computer Science, Electrical Engineering, and Economics at MIT.

David Medvedeff, Aspen RxHealth – Director

Dr. David Medvedeff is the founder and CEO of Aspen RxHealth, a company disrupting the pharmacy profession by crowd sourcing passionate pharmacists to deliver patient care services on behalf of payers and providers. Prior to starting Aspen RxHealth, David served as president and CEO of several successful healthcare companies including Gold Standard (acquired by Reed Elsevier), Avatar International (acquired by Press Ganey Associates) and VUCA Health, where he currently serves as an Executive Chairperson. David’s professional accomplishments have been recognized with numerous industry accolades including the National Prescott Award for his exemplary leadership, the Next Generation Pharmacist Technology Innovator, and is the only two-time winner of the American Pharmacists Association Foundation’s Pinnacle Award.

David served on the Board of Directors of Strata Decision Technology (acquired by Roper Technologies) and Pharmacy Quality Solutions. Today he serves on the Executive Board of the Beryl Institute and is a Board Member and previous Chairperson of the Pharmacy Quality Alliance.

David studied organic chemistry at the University of Florida, where he earned his Doctor of Pharmacy and Master of Business Administration. He has served on the faculty of College of Pharmacy as an Associate Professor and has received the Outstanding Alumnus and the Outstanding Service Awards from the College. 

Michael Greeley, Flare Capital Partners – Director

Michael is a cofounder and General Partner at Flare Capital Partners, a leading healthcare technology venture firm based in Boston, MA, focused on the transformation of the “business of healthcare.” Previously, Michael was the founding General Partner of Flybridge Capital Partners, and earlier in his career was with Polaris Partners, as well as held positions at Wasserstein Perella & Co. and Morgan Stanley & Co. 

Current and prior board seats include Aspen RxHealth, BlueTarp Financial, Circulation, Cohere Health, Explorys, Functional Neuromodulation, HealthVerity, higi, Iora Health, MicroCHIPS, Nuvesse, PolyRemedy, Predictive Biosciences, Predilytics, T2 Biosystems, TARIS Biomedical, VidSys and Welltok. Additionally, Michael served on the board of International Data Group, the founding partner of IDG Capital, a leading venture capital fund in China and other important innovation centers in Asia, and is on the board of The Forsyth Institute, the leading Harvard-affiliated oral health research organization. Michael serves on various innovation and investment advisory boards for Advocate Aurora Health, Boston Children’s Hospital, Cleveland Clinic, and MedStar Health, as well as serving on the Governor’s Digital Health Council and the Massachusetts Technology Collaborative. 

Michael also serves on the Investment Committee for the Partners Innovation Fund and on is the Advisory Board of Harvard Business School’s Health Care Initiative. He was past chairman of the New England Venture Capital Association and on the board and executive committee of the National Venture Capital Association. Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School. 

Colin Drylie, Humana – Director

Combining experiences as a strategist, designer and entrepreneur, Colin Drylie has driven multiple efforts to bring human-centered design and business model innovation to life at Fortune 100 companies, including for the past six years at Humana. He has over 15 years of experience driving innovation and transformation across healthcare, telecom, media, consumer products, manufacturing, and non-profit sectors. 

Colin is currently Vice President, Product and Strategy, at Humana with responsibility for sales strategy and digital transformation, and customer segment accountability for growth, experience and health outcomes for Dual Eligible, Veteran and Multicultural populations. Colin earned a Bachelor of Commerce (Honors with Distinction) from Queen’s University, in Ontario, Canada. He has served on Aspen’s board since the company’s founding in 2018. 

Steve Kraus, Bessemer Venture Partners – Director

Steve Kraus is a partner at Bessemer in the Cambridge office and a world-renowned healthcare investor. He is the author of Bessemer’s 10 Laws of Healthcare and is a co-host of A Healthy Dose podcast. Steve currently sits on the boards of Bright Health, Hinge Health, Ginger, Welltok, Artemis Health, Groups, Qventus, Alcresta, and is a board observer at Collective Medical Technologies.

Prior to joining Bessemer, Steve worked for a growth-stage, private equity firm as a management consultant at Bain & Company. He has also worked on several different political campaigns throughout his career.

He serves as an Observer at Beth Israel Deaconess Medical Center, an advisor to Boston Children’s Hospital and the Harvard Business School’s Center for Entrepreneurship, and on the investment committees of BCBS Massachusetts and Rock Health.

Steve graduated summa cum laude from Yale University and earned his MBA from Harvard, where he was a Baker Scholar.

Mitch Betses, Independent – Director

Mitch is a principled and purpose driven healthcare executive with over 30 years of experience developing and delivering solutions to advance health outcomes, while improving the patient experience, and lowering costs. His long tenure as an executive for nearly every major division of CVS has given him the unique combination of business acumen and strategic critical thinking skills with the ability to foresee and respond to marketplace shifts in a rapidly evolving healthcare landscape. His proven and repeatable track record of leading turn-around and transformation initiatives to change the trajectory of an operation with a high sense of urgency is made possible by his ability to combine strategic priorities with real world pragmatism while simultaneously solving for immediate challenges, mid-range improvement opportunities, and foundational pillars for long term success. 

Current and prior board seats include Aspen RxHealth and Pharmacy Quality Alliance. Mitch earned a B.S. in Pharmacy from The Massachusetts College of Pharmacy.

Bruce Meadows, Takeda Digital Ventures – Observer

Originally trained as a molecular biologist, Bruce is a systems thinker who works seamlessly across the complex worlds of science, technology, and finance to create sustainable value for founders, employees, and investors at every stage of value creation, from early incubation to liquidity. A seasoned operator with direct P&L experience bringing medical devices to market to drive growth, he is an asset to leadership teams, helping them access qualified capital amid shifting market dynamics in highly competitive, highly regulated global healthcare markets. As an experienced venture and private equity investor in pharmaceuticals, medical devices, and digital health, he brings operational insights and novel thinking to forge cutting-edge business models, chart viable paths to growth and profitability, and oversee investor relations with rigor and transparency from seed to liquidity.

Bruce has more than 20 years’ experience as an active investor in healthcare through leading private equity and venture capital funds in Australia and Europe, including GBS Venture Partners (Formerly Rothschild Bioscience); MTIP, MD Start, and Ares Life Sciences.

Jennifer Carter, McKesson Ventures – Observer

Jennifer Carter is a partner and vice president of operations for McKesson Ventures.  In addition to investing, Jennifer oversees operations for the firm which includes talent, budget, and portfolio development. 

Prior to joining McKesson Ventures, Jennifer spent 15 years at McKesson Corporation in various roles across the McKesson enterprise ranging from marketing, business development, strategy, and sales operations.  Jennifer currently sits on the boards of Augmedix and Matternet.  Jennifer holds a B.S. in Economics from Boston College.